InnovAge (INNV) Q4 2026 Earnings Call Transcript

InnovAge reported FY2026 revenue of $989.7 million, up 15.9%, and adjusted EBITDA of $94.6 million, up 174.2%, with center-level contribution margin expanding 500bps to 23.0%. The company narrowed its annual net loss to $0.7 million from $35.3 million despite $52.4 million of legal accruals, while Q4 net income reached $9.8 million. FY2027 guidance calls for $1.05-$1.085 billion in revenue, $105-$115 million in adjusted EBITDA, and 5%-7.5% census growth, though unfinalized Medicaid reimbursement rates in California and Colorado—70% of census—remain a key risk. Management is targeting further efficiency gains through utilization management, in-house care capabilities and AI-enabled clinical, scheduling and medication-management tools.

Analysis

INNV’s investable change is the quality of EBITDA: the next leg must come from utilization control and fixed-cost absorption rather than unusually favorable reimbursement. That makes center-level referral, pharmacy, transportation, and staffing metrics more important than headline revenue. If management can hold contribution margin near current levels while adding 5%-7.5% census, the business should cross into sustainably positive GAAP earnings once legal costs normalize, supporting a rerating from a turnaround discount toward value-based-care peers.

The near-term asymmetry is reimbursement concentration. California and Colorado rate determinations affect roughly 70% of membership, while the V28 transition begins to matter in January; a seemingly modest 100 bp adverse blended-rate outcome could remove roughly $10 million of annualized revenue and materially consume guided EBITDA growth given the narrow $10 million guidance range. Conversely, dementia-heavy acuity may make INNV relatively more resilient than diversified MA organizations under V28, creating upside if final state rates are merely neutral rather than punitive.

Management’s AI claims are not yet underwriting items: fewer referrals only creates value if avoided specialist spend is not offset by internal clinician capacity, higher downstream acuity, or implementation expense. The more credible 6-18 month catalyst is capacity unlock at existing centers, which raises ROIC versus de novos and makes acquisitions selectively accretive. A policy expansion into Medicare-only seniors is a free option, but should receive no valuation credit until CMS/CMMI produces a formal model, funding mechanism, and enrollment rules.

Contrarian view: consensus may focus on the EBITDA step-up and miss the litigation overhang. The accrual does not establish final cash cost or eliminate compliance risk; any renewed enforcement action would impair state relationships precisely when rate negotiations and expansion approvals matter. Thus this is an execution-and-regulatory spread trade, not a clean AI or policy-growth story.

Key Decisions for Investors

• Initiate a small long INNV only after California and Colorado rate outcomes are finalized or after a post-results pullback; target a 6-12 month hold. Underwrite upside to the top end of EBITDA guidance plus normalized legal expense, but cap initial sizing because a 100 bp blended reimbursement shortfall can erase much of incremental EBITDA.
• Use a catalyst-driven add rule: increase INNV if first-half FY27 census tracks at least 6% growth and center contribution margin remains above 22%; these would validate that margin durability is operational rather than rate-driven. Reduce if margin falls below 21% or enrollment decelerates below 5%.
• Avoid treating AI as a standalone long catalyst. Set an alert for disclosed PMPM savings, specialist-referral reduction, transportation productivity, or measurable center-capacity gains; absent quantified unit economics, management commentary should not change valuation.
• For market-neutral healthcare exposure, consider long INNV versus short a broad Medicare Advantage proxy such as HUM only after state rates are resolved: INNV’s dementia-acuity mix may be comparatively advantaged by V28, while HUM retains broader utilization and reimbursement exposure. Exit on adverse California/Colorado rates, new material legal action, or a widening medical-cost trend.